帕博利珠单抗治疗成人急性淋巴细胞白血病可测量残留病的2期研究
这项2期研究评估帕博利珠单抗200 mg静脉给药每3周一次,在化疗后仍可检测到可测量残留病的成人B细胞或T细胞急性淋巴细胞白血病患者中的疗效,主要终点为完全可测量残留病缓解率;12例中仅1例(8%)获得完全可测量残留病缓解,持续3周,中位总生存期为12.7个月,研究提前停止入组。
要点
- 帕博利珠单抗200 mg静脉给药每3周一次,12例中仅1例(8%)获得完全可测量残留病缓解,持续3周。
- 唯一缓解者既往接受过造血细胞移植和CD19靶向嵌合抗原受体修饰T细胞治疗,并发生3级史蒂文斯-约翰逊综合征。
- 自入组起中位总生存期为12.7个月,帕博利珠单抗对可测量残留病活性极小但总体耐受良好。
核心结论
- 帕博利珠单抗对可测量残留病活性极小,但总体耐受良好。
- 这些数据可与正在进行的急性淋巴细胞白血病抗PD-1联合研究相比较,并进一步确立了专门针对可测量残留病患者开展试验的作用。
研究设计与样本
- 2期研究,纳入化疗后骨髓穿刺仍可检测到可测量残留病的成人B细胞或T细胞急性淋巴细胞白血病患者(费城染色体阳性者加用ABL激酶抑制剂)。
- 帕博利珠单抗200 mg静脉给药每3周一次,主要终点为完全可测量残留病缓解率,研究提前停止入组。
- 试验注册号为NCT02767934。
主要发现
- 12例中仅1例(8%)获得完全可测量残留病缓解,持续3周。
- 该缓解者既往接受过造血细胞移植和CD19靶向嵌合抗原受体修饰T细胞治疗,并且是唯一发生帕博利珠单抗免疫相关不良事件(3级史蒂文斯-约翰逊综合征)的患者。
- 自入组起中位总生存期为12.7个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究提前停止入组,仅12例可评估。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The presence of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) confers a poor prognosis. CD19-targeted immunotherapy is effective against MRD but is logistically challenging, potentially toxic, and not applicable to T-cell ALL. We thus hypothesized that inhibition of PD-1 with pembrolizumab could also be effective for MRD, but without lineage restriction. The primary objective of this phase 2 study was to evaluate the efficacy of pembrolizumab in patients with ALL and MRD. Key eligibility criteria included adults with B- or T-cell ALL and MRD detectable by multiparameter flow cytometry or quantitative polymerase chain reaction from bone marrow aspirate (BMA) despite chemotherapy (plus ABL kinase inhibitor if Philadelphia chromosome positive). Pembrolizumab 200 mg IV was given every 3 weeks. Response was assessed by BMA using methods that previously detected MRD. The primary end point was complete MRD response rate. We stopped enrollment early; only 1 of 12 (8%) experienced a complete MRD response, which lasted 3 weeks. Interestingly, this patient had previously received hematopoietic cell transplantation and CD19-targeted chimeric antigen receptor-modified T-cell therapy and was the only patient to experience an immune-related adverse event from pembrolizumab (grade 3 Stevens-Johnson syndrome). Median overall survival from enrollment was 12.7 months. In summary, pembrolizumab had minimal activity against MRD but was generally well tolerated. These data can be compared with ongoing anti-PD-1 combination studies in ALL, and they further establish the role of trials specifically for patients with MRD. This trial was registered at www.clinicaltrials.gov as #NCT02767934.
引用
- Cassaday RD, Garcia KA, Fromm JR, et al. Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 32692850. doi:10.1182/bloodadvances.2020002403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。